 SOUTH SAN FRANCISCO, Calif., March 10, 2021 GLOBE NEWSWIRE -- RAPT Therapeutics, Inc. Nasdaq: RAPT, a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced several upcoming preclinical poster presentations at the American Association for Cancer Research annual meeting demonstrating promise and potential of its pipeline of anti-cancer agents. 